Dose-response Study of Exendin-9,39 on Glucose Metabolism

NCT01218633 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1

Interventions

DRUG: saline infusion
DRUG: GLP-1-9,36 infusion
DRUG: Exendin-9,39 at low dose
DRUG: Exendin-9,39 at high dose

Sponsor

Adrian Vella